Clomiphene Citrate Market

By Indication;

PCOS, Secondary Amenorrhea, Psychogenic Amenorrhea, Amenorrhea Galactorrhea Syndrome, and Others

By Formulation;

Tablets and Oral Solutions

By Route of Administration;

Oral and Intramuscular

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

By Application;

Female Infertility Treatment and Male Infertility Treatment

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn122409864 Published Date: June, 2025 Updated Date: July, 2025

Clomiphene Citrate Market Overview

Clomiphene Citrate Market (USD Million)

Clomiphene Citrate Market was valued at USD 1,298.33 million in the year 2024. The size of this market is expected to increase to USD 1,876.16 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.4%.


Clomiphene Citrate Market

*Market size in USD million

CAGR 5.4 %


Study Period2025 - 2031
Base Year2024
CAGR (%)5.4 %
Market Size (2024)USD 1,298.33 Million
Market Size (2031)USD 1,876.16 Million
Market ConcentrationMedium
Report Pages343
1,298.33
2024
1,876.16
2031

Major Players

  • Sanofi S.A.
  • Par Pharmaceutical
  • Merck & Co. Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Unichem Laboratories Ltd.
  • Emcure Pharmaceuticals Ltd
  • Serum Institute of India Pvt. Ltd

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Clomiphene Citrate Market

Fragmented - Highly competitive market without dominant players


The Clomiphene Citrate Market is witnessing notable momentum, driven by increasing infertility diagnoses and the widespread use of ovulation-inducing agents. Clomiphene is recommended in over 48% of ovulation induction cases, underlining its significant clinical relevance. Its growing adoption stems from both therapeutic effectiveness and increased accessibility across medical settings.

Widespread Adoption for Affordability
Due to its low-cost profile and consistent clinical outcomes, clomiphene citrate remains the frontline fertility drug for many providers. Nearly 55% of healthcare professionals consider it the most viable option for initial infertility management. Its cost-efficiency makes it an attractive solution across diverse patient populations.

Changing Patient Attitudes Toward Fertility Care
With 65% of women now pursuing fertility assessments within the early stages of conception efforts, clomiphene citrate prescriptions are on the rise. This shift in patient behavior has contributed significantly to increased demand, as more individuals proactively seek fertility interventions powered by trusted, evidence-based therapeutics.

Innovations Reinforcing Market Stability
Clomiphene citrate continues to benefit from research-driven improvements, including combination protocols and alternate formulations. Approximately 42% of clinical trials involving ovulation therapies incorporate clomiphene, which speaks to its enduring relevance. Such innovations help ensure continued clinical utility and long-term presence in treatment regimens.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Indication
    2. Market Snapshot, By Formulation
    3. Market Snapshot, By Route of Administration
    4. Market Snapshot, By Distribution Channel
    5. Market Snapshot, By Application
    6. Market Snapshot, By Region
  4. Clomiphene Citrate Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing infertility rates
        2. Rising demand for ovulation-inducing drugs
        3. Advancements in reproductive technologies
        4. Growing awareness about fertility treatments
        5. Expansion of healthcare infrastructure
      2. Restraints
        1. Side effects and risks
        2. Stringent regulatory norms
        3. Limited accessibility in rural areas
        4. Alternative treatment options
        5. Patent expiration challenges
      3. Opportunities
        1. Emerging markets expansion
        2. Development of novel formulations
        3. Collaborations for research
        4. Personalized medicine approaches
        5. Telemedicine adoption
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Clomiphene Citrate Market, By Indication, 2021-2031 (USD Million)
      1. PCOS
      2. Secondary Amenorrhea
      3. Psychogenic Amenorrhea
      4. Amenorrhea Galactorrhea Syndrome
      5. Others
    2. Clomiphene Citrate Market, By Formulation, 2021-2031 (USD Million)

      1. Tablets

      2. Oral Solutions

    3. Clomiphene Citrate Market, By Route of Administration, 2021-2031 (USD Million)

      1. Oral

      2. Intramuscular

    4. Clomiphene Citrate Market, By Distribution Channel, 2021-2031 (USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    5. Clomiphene Citrate Market, By Application, 2021-2031 (USD Million)

      1. Female Infertility Treatment

      2. Male Infertility Treatment

    6. Clomiphene Citrate Market, By Geography, 2021-2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Sanofi S.A.
      2. Par Pharmaceutical
      3. Merck & Co. Inc.
      4. Teva Pharmaceutical Industries Ltd.
      5. Cipla Inc.
      6. Unichem Laboratories Ltd.
      7. Emcure Pharmaceuticals Ltd
      8. Serum Institute of India Pvt. Ltd
  7. Analyst Views
  8. Future Outlook of the Market